Antidepressant Treatment of AIDS Related Depression.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Drug: Imipramine hydrochloride |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
To test the effectiveness treating AIDS related depression with imipramine hydrochloride.
Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status.
This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
- Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented.
- May have been alcoholic or drug abuser 6 months previous.
- Unspecified
- CD4 Unspecified.
Exclusion Criteria:
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Non ambulatory patients or those requiring extensive help in self care are excluded.
- Current alcohol or drug abuse.
- Unspecified
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00000390 History of Changes |
| Other Study ID Numbers: | 87-DEP |
| Study First Received: | January 17, 2000 |
| Last Updated: | June 23, 2005 |
| Health Authority: | Unspecified |
Keywords provided by National Institute of Mental Health (NIMH):
|
Adult Acquired Immunodeficiency Syndrome Depression Female Human Imipramine |
Male Middle Age Acquired Immunodeficiency Syndrome -- *complications Depression -- *drug therapy Depression -- etiology Imipramine -- *therapeutic use |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome Depression Depressive Disorder HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases Behavioral Symptoms Mood Disorders |
Mental Disorders Antidepressive Agents Imipramine Psychotropic Drugs Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Antidepressive Agents, Tricyclic Adrenergic Uptake Inhibitors Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013